Pancreatic Cancer Research

ResearcherLund UniversityNo recent work listed

György Marko‐Varga

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7140-8925; OpenAlex author ID A5025688013. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 3 papers · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 1 paper

Papers 10

  1. Lipid Metabolic Reprogramming Extends beyond Histologic Tumor Demarcations in Operable Human Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-0396↗
  2. YAP1 is an independent prognostic marker in pancreatic cancer and associated with extracellular matrix remodeling. Co-author DOI 10.1186/s12967-020-02254-7↗
  3. Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue. Co-author DOI 10.1016/j.ebiom.2019.04.008↗
  4. Alpha-1-acid glycoprotein 1 is upregulated in pancreatic ductal adenocarcinoma and confers a poor prognosis. Co-author DOI 10.1016/j.trsl.2019.06.003↗
  5. Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.23929↗
  6. Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/bjs.10471↗
  7. Characterization of histone-related chemical modifications in formalin-fixed paraffin-embedded and fresh-frozen human pancreatic cancer xenografts using LC-MS/… Co-author DOI 10.1038/labinvest.2016.134↗
  8. Histone profiling reveals the H1.3 histone variant as a prognostic biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-017-3834-z↗
  9. Protein deep sequencing applied to biobank samples from patients with pancreatic cancer. Last author DOI 10.1007/s00432-014-1817-x↗
  10. The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science. Co-author DOI 10.1186/1479-5876-12-87↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Roland E. Andersson · 9 shared papers, 2014–2020 · strength 0.70
  2. Daniel Ansari · 9 shared papers, 2014–2020 · strength 0.70
  3. Monika Posaric Bauden · 8 shared papers, 2015–2020 · strength 0.65
  4. Dingyuan Hu · 4 shared papers, 2018–2020 · strength 0.35
  5. Qimin Zhou · 4 shared papers, 2018–2020 · strength 0.35
  6. Bodil Andersson · 2 shared papers, 2015–2017 · strength 0.13
  7. Elina Ikonen · 1 shared paper, 2022 · strength 0.13
  8. Juho Pirhonen · 1 shared paper, 2022 · strength 0.13
  9. Hanna E. Seppänen · 1 shared paper, 2022 · strength 0.13
  10. Caj H. Haglund · 1 shared paper, 2022 · strength 0.13
  11. Pauli Antero Puolakkainen · 1 shared paper, 2022 · strength 0.13
  12. Mengtao Zhou · 1 shared paper, 2019 · strength 0.08
  13. Linus Aronsson · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.